GlassScriptPhysician profile
Douglas A Perry
NPI 1306844121
$8,857.59
in general payments reported to CMS, 2019-2025
51 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $615 · 2021: $842 · 2022: $1,018 · 2023: $1,478 · 2024: $1,664 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,186 · Long Term Medical Supply Or Device Loan: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,186.32 |
| Long Term Medical Supply Or Device Loan | $123.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,482.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,001.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $935.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $801.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $537.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.05 | 2019-2025 | Jardiance, Ofev |
| Esperion Therapeutics, INC. | $364.60 | 2020-2025 | Nexletol |
| Amgen INC. | $289.73 | 2019-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $222.09 | 2019-2025 | Veozah |
| Dexcom, INC. | $191.94 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $187.23 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $185.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $174.90 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $165.55 | 2022-2024 | Nuzyra |
| Abiomed | $143.08 | 2024-2025 | Impella |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.